Nearly 1,000 Medicines In Development To Help Patients In Their Fight Against Cancer

America’s biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of canceraffecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). These potential medicines, which are either in clinical trials or under review by the Food and Drug Administration, include 121 for lung cancer, 117 for lymphoma and 111 for breast cancer.

“Despite amazing strides in the ongoing battle against cancer, the many forms of this disease remain a major public health challenge for patients, their families, healthcare providers. Additionally, cancer is a burden on economies in the United States and throughout the world,” said PhRMA President and CEO John J. Castellani. “The ceaseless efforts of biopharmaceutical researchers in America have brought new and improved treatment to patients, providing options that didn’t exist before. This report reflects stories of remarkable science, individual perseverance and an unwavering commitment to patients.”

Over the last few decades, significant progress in biopharmaceutical research and development has led to steady improvements in cancer survivorship rates in the U.S. According to the American Cancer Society, the cancer death rate fell 22% for men and 14% for women between 1990 and 2007, which translated to 898,000 fewer deaths from the disease in this period (see more cancer rates in our map: Cancer Across the United States).

In addition to the benefits for patients and their families, declines in cancer death rates have a tremendous economic impact. The National Institutes of Health estimates overall costs for cancer in 2007 at $226.8B: $103.8B for direct medical costs (all health expenditures) and $123B for indirect mortality costs (cost of lost productivity due to premature death). According to recent research from the University of Chicago, reducing cancer death rates by 10 percent would be worth roughly $4.4T in economic value to current and future generations.

America’s biopharmaceutical researchers are working on many new cutting-edge approaches to fight cancer. Examples include:

• A medicine that interferes with the metabolism of pancreatic cancer cells by depriving them of the energy provided by glucose.
•  A medicine for acute myeloid leukemia (AML) that inhibits cancer cells with a mutation found in about a third of AML sufferers.
• A therapy that uses nanotechnology to target the delivery of medicines to prostate cancer cells, potentially overcoming some limitations of existing treatments.

“Since the war on cancer was declared in the early 1970s, biopharmaceutical research companies have laid a significant stake in the ground by helping millions of patients worldwide manage or even beat this disease,” said Castellani. “Future medical advancements are our best hope for lessening the burden of cancer to patients, their families and society.”

The continuing commitment of biopharmaceutical research companies to battling cancer and other diseases is evident here in the U.S. According to the National Science Foundation, the biopharmaceutical sector accounts for nearly 20 percent of all domestic R&D funded by U.S. businesses – the single largest share of all U.S. business R&D.

About The Pharmaceutical Research and Manufacturers of America (PhRMA)

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5B in 2011 in discovering and developing new medicines. For more information, visit http://www.phrma.org

SOURCE: The Pharmaceutical Research and Manufacturers of America (PhRMA)